Tranzyme Pharma Receives FDA Fast Track Status for Its Oral GI Prokinetic Drug Candidate TZP-102

Jul 27, 2009 - Tranzyme Pharma today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's oral gastrointestinal (GI) prokinetic drug candidate TZP-102, for the treatment of gastroparesis in diabetic patients.

The details can be read here.